[{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Announces Publication of Abstracts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Presents Updated Data from MERECA Trial of Ilixadencel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Published Phase I\/II Clinical Trial Results of Ilixadencel in Gastrointestinal Stromal Tumors in Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB (publ) Announces Next Safety and Enrollment Update for Phase Ib\/II ILIAD Combination Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"VU University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum Review Data Safety Monitoring Board for Phase Ib Part of ILIAD Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Publishes Phase II MERECA Trial Results of Ilixadencel in Kidney Cancer in European Urology Open Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mendus","sponsor":"Minaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mendus AB: Mendus Secures Manufacturing Partner For Establishing Potential Pivotal Trial-stage And Commercial Production Of DCP-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus To Report Positive Clinical And Preclinical Data In Ovarian Cancer At The European Society Of Gynaecological Oncology 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Mendus","sponsor":"Flerie","pharmaFlowCategory":"D","amount":"$29.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mendus Announces a Directed Share Issue and a Fully Secured Rights Issue of Units Totaling Approximately SEK 317 Million in Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus Receives U.S. FDA Fast Track Designation for Vididencel in Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mendus","sponsor":"Australasian Leukaemia & Lymphoma Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mendus and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus Provides Business Update and Outlook for Vididencel Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Mendus
DCP-001 (vididencel) is an off-the-shelf intradermal allogenic dendritic cell-based vaccine, which is being evaluated for the treatment of acute myeloid leukemia.
The collaboration aims to support Mendus to focus on the development of its lead product candidate DCP-001 (vididencel) in combination with oral azacitidine as a potential novel maintenance treatment in acute myeloid leukemia.
DCP-001 (vididencel), an allogeneic dendritic cell vaccine, which is investigated for the treatment of acute myeloid leukemia and ovarian cancer and received for fast track designation from the U.S. Food and Drug Administration.
Mendus intends will use the net proceeds for the clinical development of DCP-001 (vididencel), an allogeneic dendritic cell vaccine, in AML maintenance and ovarian cancer.
DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial in ovarian cancer.
The initial data demonstrates that DCP-001, an off-the-shelf intradermal dendritic cell-based vaccine was safe and well-tolerated, confirming the benign safety profile of DCP-001 observed in multiple completed and ongoing clinical trials.
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established in vivo cancer model.
Ilixadencel (activated allogeneic dendritic cells) is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors, has consistently demonstrated signs of efficacy and maintained a positive safety and tolerability profile.
Lead Product(s):
Activated Allogeneic Dendritic Cells
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following treatment with DCP-001.
In vivo and in vitro data support evaluation of DCP-001 as a potential combination therapy with 5-AZA+VEN in AML and related hematological malignancies and demonstrated stronger tumor volume reduction in combination than either vaccination or drug treatment alone.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
